Diabetes

High-dose vitamin D3 shows promise in improving metabolic health for type 2 diabetes patients, enhancing glycemic control alongside traditional treatments.

GLP-1 therapies gain popularity, but patient adherence struggles due to fragmented support and emotional barriers.

Gestational diabetes significantly impacts postpartum cardiovascular health, especially in women over 35, highlighting the need for timely interventions.

Episode 6 explores what pharmacists in the diabetes space need to know about outcomes data, safety, and when to escalate LDL-lowering therapy.

Oral semaglutide (Rybelsus) reduces the risk of major adverse cardiovascular events in adults with high-risk type 2 diabetes, based on data from the SOUL trial.

In an exploration of key stakeholders’ perspectives, researchers assess a lifestyle intervention for cardiometabolic health among women during or after pregnancy.

Pharmacists play a vital role in integrating diabetes and depression care, enhancing patient outcomes through screening, individualized treatment, and collaborative approaches.

Pharmacists play a crucial role in preventing cardiometabolic conditions through screenings, risk assessments, and lifestyle interventions, enhancing public health.

Episode 5 explores insulin management as well as the insulin products, doses, and administration tools all pharmacists should be familiar with for their patients with diabetes.

Person-centric packaging enhances medication adherence for type 2 diabetes patients, simplifying therapy and improving outcomes, according to recent studies.

Pharmacists enhance diabetes care through text messaging interventions, improving medication adherence and glycemic control in patients with complex treatment plans.

In patients with diabetes and various levels of UACR, researchers aimed to uncover both the relative and absolute effects of SGLT2 inhibitors.

A study explored how SGLT2 inhibitors impact the kidney, specifically whether effects varied by estimated glomerular filtration rate (eGFR) or albuminuria.

Oral semaglutide 25 mg shows significant benefits in weight loss and cardiovascular health for patients with obesity, enhancing overall well-being.

Finerenone shows promise in reducing kidney damage for type 1 diabetes patients, marking a significant advancement in chronic kidney disease treatment.

Through diabetes education and initiatives focused on community health care, Clipper F. Young, PharmD, MPH, CDCES, BC-ADM, BCGP, is making a difference for patients and the pharmacy profession.

A study reveals tailored glucose monitoring intervals for type 2 diabetes patients based on HbA1c levels, enhancing long-term management strategies.

Episode 4 of Wicked Good Cardiometabolic Chat explores SGLT2 inhibitors and their efficacy beyond diabetes outcomes alone.

The regimen did not show signs of significant hypoglycemia and had a low prevalence of edema despite modest weight gain.

A study reveals that lower baseline BMI and early weight loss with liraglutide enhance significant weight loss outcomes in patients with type 2 diabetes.

FDA approves oral semaglutide for reducing cardiovascular risks in high-risk type 2 diabetes patients, enhancing treatment options and outcomes.

Orforglipron demonstrates superior glycemic control in phase 3 trials, showing promise as a new treatment for type 2 diabetes.

The immediacy of data from these monitors is essential in educating patients on managing their chronic disease states.

As shortages end, pharmacies that compound GLP-1s face lawsuits, stricter board oversight, and tougher FDA enforcement.

Pharmacists can help patients maintain muscle mass, meet their protein needs, and prevent nutritional deficiencies through evidence-based guidance that supports better overall health.